I agree not much new. i noticed that Nader did say they want the mono trials to have the 300 patients so there is not going to be an attempt to reduce in the future. Nader said they want to have a large # to show the effectiveness across a large sample set for the data. i agree with that, any big pharma wants to know it works and a large sample set will show that. Nader also mentioned when asked about if they are in talks with big pharma that typically big pharma is patient and waits before a buyout. they are not looking to buy at the lowest price, more interested in a sure thing.
News 
Market Data 
Discover 
